ReviewBiochemistry2026
From Neoantigens to Nanocarriers: Modern Methods and Modalities in Using Peptides for Cancer Vaccination.
Review in Biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of cancer vaccination depends on the ability of therapeutics to sustain prolonged immune activation, leading to the destruction of tumor cells. However, only a few therapeutic cancer vaccines have been FDA-approved due to challenges in targeting and eliciting a sufficiently strong immune response. Peptides have emerged as promising drugs owing to their ability to interact with cell-surface receptors and their low manufacturing cost. Despite the peptides' positive characteristics, additional research is needed to develop more effective methods for using peptides to stimulate the immune system for a sustained period to induce tumor cell regression. This review focuses on recent work in peptide-based vaccine design and development, aiming to determine the optimal formulation of peptide vaccines by identifying and isolating neoantigens for tumor targeting, thereby delivering peptide antigens to specific locations. The expansion of the current landscape of cancer treatments, including peptide vaccines and combination therapies, is revolutionizing the possibilities for patient care and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.